By OPEN MINDS Circle
On November 9, 2021, the Massachusetts Medicaid program (MassHealth) added two Pear Therapeutics, Inc. prescription digital therapeutics (PDTs) — reSET® and reSET-O® — to the November 2021 MassHealth Drug List Summary Update. Both reSET and reSET-O have been authorized by the U.S. Food and Drug Administration (FDA) for treatment of addiction disorder and opioid use disorder, respectively. Effective November 1, 2021, MassHealth is covering reSET® and reSET-O® for MassHealth members in addiction treatment. The PDTs will be paid for through MassHealth’s Pharmacy Online Processing System (POPS) and do not require prior authorization. MassHealth has about 2 million enrollees.
The reSET PDT is a software application intended to provide cognitive behavioral therapy, as an adjunct to a contingency management system, for people 18 years of age and older, who are currently enrolled in outpatient addiction treatment under the supervision of a clinical professional. reSET is indicated as a 12-week (90 day) prescription-only treatment for consumers with addiction disorder, who are not currently on opioid replacement therapy, who do not abuse alcohol solely, or who do not abuse opioids as their primary substance of abuse. reSET is intended increase the consumer’s abstinence level and increase retention in an outpatient treatment program.
The reSET-O PDT is a 12-week (84 day) software application intended to increase treatment retention of consumers with opioid use disorder (OUD) in outpatient treatment. The PDT provides cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for consumers 18 years or older who are currently under the supervision of a clinical professional.
Pear Therapeutics develops and markets PDTs for multiple therapeutic areas. Three of its PDTs have been authorized by the FDA for commercial use; they are reSET®, reSET-O®, and Somryst® for the treatment of chronic insomnia. The PDTs are designed to engage consumers in treatment and provide tracking tools for clinical professionals. Its PDTs are designed to collect real world data for use by prescribing clinical professionals and for population health management by payers and health systems.
For more information about Pear Therapeutics, contact: Meara Murphy, Director, Corporate Communications, Pear Therapeutics, 201 Mission Street, San Francisco, California 94105; Email: meara.murphy@peartherapeutics.com; Website: https://peartherapeutics.com/
For more information about the MassHealth coverage, contact: Kate Reilly, Director of Administration and Communications, Massachusetts Executive Office of Health and Human Services, 1 Ashburton Place, Boston, Massachusetts 02108; 617-312-1976; Email: Katelyn.Reilly@mass.gov; or Kayla Rosario-Munoz, Media Relations Manager, Massachusetts Executive Office of Health and Human Services, 1 Ashburton Place, Boston, Massachusetts 02108; 857-248-1104; Email: Kayla.RosarioMunoz@mass.gov; Website: https://www.mass.gov/service-details/covered-services